| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $14.6M | — | +328.1% |
| SG&A Expense | $7.5M | — | +148.0% |
| Pre-tax Income | -$19.1M | — | -259.1% |
| Income Tax | $0 | — | — |
| Net Income | -$19.1M | — | -259.0% |
| EPS (Basic) | -$0.67 | — | +95.5% |
| EPS (Diluted) | -$0.67 | — | +95.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $320.7M | +28.2% | — |
| Short-term Investments | $45.0M | -0.2% | — |
| Current Assets | $389.1M | +26.1% | — |
| Total Assets | $393.5M | +25.7% | — |
| Current Liabilities | $10.9M | +46.5% | — |
| Total Liabilities | $14.8M | +27.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$23.3M | — | -186.5% |
| Capital Expenditures | $32K | — | +52.4% |
| Investing Cash Flow | -$32K | — | -100.6% |
| Financing Cash Flow | $93.8M | — | — |
| Free Cash Flow | -$23.3M | — | -186.2% |
| — |
| Stockholders' Equity | $378.7M | +25.7% | +481.2% |